Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment

Psoriasis Vulgaris Clinical Trial

Official title:

Evaluation of the Efficacy and Safety of Indigo Naturalis Extract in Oil in the Topical Therapy of Psoriasis Vulgaris: Dosage Determination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01735864
• Other study ID #: NSC101-2325-B-182-018
• Status: Completed
• Phase: N/A
• Start date: November 2012
• Est. completion date: April 2014

Study information

• Verified date: July 2019
• Source: Chang Gung Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The use of refined indigo naturalis (indigo naturalis extract in oil, INEO)ointment to treat psoriasis has been proven effective in our previous study. This study aims to evaluate the efficacy and safety of INEO ointment, and further determine the optimal concentration of INEO ointment (per gram of ointment containing either 200 μg, 100 μg, 50 μg or 10 μg of indirubin) in treatment of various local skin signs and thickness of psoriasis plaque.

Description:

The use of indigo naturalis ointment to treat psoriasis has been proven effective in our previous clinical studies which demonstrated the efficacy and safety of topical indigo naturalis ointment, showing its ability to provide significant improvement of psoriatic skin lesions.

We developed a new formulation in which indigo naturalis powder is refined and reduces the blue discoloration of skin and clothes, making the treatment more user-friendly. We had observed an equivalent efficacy of the refined form of indigo naturalis (INEO) ointment on treating psoriasis as the crude form. However, it is necessary to determine an appropriate dosage of the refined form regarding its efficacy and safety.

This is a double-blind, 4-arm parallel study. The aim of this study is

1. To determine an appropriate dosage of indirubin in INEO ointment, regarding its efficacy and safety.

2. To evaluate the efficacy of INEO ointment in different local skin signs of plaque lesions.

3. To evaluate the efficacy of INEO in different traditional Chinese medicine clinical syndromes of psoriasis vulgaris.

4. To investigate the effects of INEO ointment on the immune system.

5. To evaluate the effects of INEO ointment in improving quality of life after treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

• Aged 20 - 65 years, men or women.

• Diagnosed as mild to moderate plaque-type psoriasis by the dermatologist, with psoriasis for a minimum of 1 year.

• Plaque psoriasis involving <20% of BSA and with PASI <20.

• Female patients of child-bearing age with negative pregnancy test at screening.

• Female patients of childbearing age who have agreed to continue using birth control measures approved by the investigator and agree not to lactate for the duration of the study.

• Willingness to comply with study protocol.

• With signed informed consent form.

Exclusion Criteria:

• With history of topically or systematically hypersensitive to indigo naturalis or its excipient in ointment.

• With history of sensitivity to Chinese herb.

• Received systematic treatment for psoriasis within 4 weeks.

• Received topical treatment for psoriasis within 2 weeks.

• With abnormal liver or renal function, clinically significant abnormalities in hematology, severe uncontrolled metabolic syndrome,psychiatric disease, cancer or AIDS.

• Patients with pustular or erythrodermic psoriasis.

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

Intervention

Drug:
• Indirubin 200µg/g
Dosage form: Ointment Dose(s): Each gram of ointment containing 200 µg of indirubin Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
• Indirubin 100 µg/g
Dosage form: Ointment Dose(s): Each gram of ointment contains 100 µg of indirubin Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
• Indirubin 50 µg/g
Dosage form: Ointment Dose(s): Each gram of ointment contains 50 µg of indirubin Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
• Indirubin 10 µg/g
Dosage form: Ointment Dose(s): Each gram of ointment contains 10 µg of indirubin Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily

Locations

Country	Name	City	State
Taiwan	Chang Gung Memorial Hospital at Keelung	Keelung
Taiwan	Chang Gung Memorial Hospital at Taipei	Taipei
Taiwan	Chang Gung Memorial Hospital at Linkou	Taoyuan City

Sponsors (2)

Lead Sponsor	Collaborator
Chang Gung Memorial Hospital	National Science Council, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare the mean percentage change of Psoriasis Areas Severity Index (PASI) from baseline at week 8 between groups	Mean change of total score (range 0-72); Percentage change of PASI; Individual scores of scaling, erythema, and elevation by sites; Percentage of responder (>50% of improvement, defined as clinical meaningful) and non-responder (less then 50% of improvement); Percentage of subjects achieving "clear or almost clear" (defined as PASI >90% of improvement)	8 weeks
Secondary	Body surface area (BSA)involved	Compare the BSA involved change from baseline on target psoriatic lesion(cm2); Compare the percentage change from baseline on target psoriatic lesion	8 weeks
Secondary	Psoriasis Severity Index (PSI)	Mean change of total score (range 0-12) of the target psoriatic plaque; Percentage change of PSI score of the target psoriatic plaque; Clearing percentage of target psoriatic plaque (the target plaque before treatment is defined as 100%, and the clearance of lesion is defined as 0%)	8 weeks
Secondary	Efficacy in various local skin signs	Thickness: thin (<0.05 mm), intermediate (=0.05 to <1.0 mm) or thick (=1.0 mm); Size: small (<5 cm in diameter), large (>5 cm in diameter) or concurrent (i.e., two type sizes exist); Erythema (redness): light red (ruddier (light red) than peripheral normal skin) or dark red (redder (scarlet) than peripheral normal skin)	8 weeks
Secondary	Efficacy in different traditional Chinese medicine (TCM) clinical syndromes of psoriasis by PASI/PSI:	Blood-heat (??) syndrome; Blood-dryness (??) syndrome; Blood-stasis (??) syndrome	8 weeks
Secondary	Physician's Global Assessment (PGA)	0 = no sign of psoriasis, 1 = almost clear, 2 = mild, 3 = moderate, 4 = moderate to severe, and 5 = severe	8 weeks
Secondary	Subject's Global Assessment (SGA)	0 = cleared, 1 = excellent, 2 = good, 3 = fair, 4 = poor, and 5 = worse	8 weeks
Secondary	Dermatology Life Quality Index (DLQI) questionnaire		8 weeks

External Links

•   Chang Gung Medical Foundation